Jefferies Financial Group Inc. Takes $1.06 Million Position in Pediatrix Medical Group, Inc. $MD

Jefferies Financial Group Inc. bought a new stake in Pediatrix Medical Group, Inc. (NYSE:MD) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 63,410 shares of the company’s stock, valued at approximately $1,062,000. Jefferies Financial Group Inc. owned 0.07% of Pediatrix Medical Group at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its position in Pediatrix Medical Group by 30.7% in the 3rd quarter. Victory Capital Management Inc. now owns 4,126,207 shares of the company’s stock valued at $69,114,000 after buying an additional 968,553 shares during the last quarter. American Century Companies Inc. boosted its holdings in Pediatrix Medical Group by 38.9% in the third quarter. American Century Companies Inc. now owns 2,682,976 shares of the company’s stock valued at $44,940,000 after purchasing an additional 751,109 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Pediatrix Medical Group by 175.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company’s stock valued at $10,683,000 after purchasing an additional 474,186 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Pediatrix Medical Group by 669.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 476,098 shares of the company’s stock worth $6,832,000 after purchasing an additional 414,216 shares during the last quarter. Finally, Hillsdale Investment Management Inc. raised its position in shares of Pediatrix Medical Group by 75,200.0% in the 2nd quarter. Hillsdale Investment Management Inc. now owns 376,500 shares of the company’s stock valued at $5,403,000 after purchasing an additional 376,000 shares in the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Analyst Ratings Changes

MD has been the subject of a number of recent analyst reports. UBS Group decreased their price target on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating for the company in a research report on Tuesday, February 24th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th. Deutsche Bank Aktiengesellschaft set a $19.00 target price on shares of Pediatrix Medical Group in a research report on Friday, February 20th. Truist Financial reduced their price target on shares of Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating on the stock in a research report on Thursday, February 19th. Finally, Zacks Research downgraded Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 23rd. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $19.80.

Pediatrix Medical Group Trading Down 1.9%

NYSE MD opened at $19.42 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.66 and a current ratio of 1.66. Pediatrix Medical Group, Inc. has a one year low of $11.84 and a one year high of $24.99. The company has a 50-day simple moving average of $20.97 and a 200-day simple moving average of $19.99. The firm has a market capitalization of $1.61 billion, a PE ratio of 10.01 and a beta of 0.79.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Thursday, February 19th. The company reported $0.50 earnings per share for the quarter, missing the consensus estimate of $0.53 by ($0.03). Pediatrix Medical Group had a return on equity of 19.59% and a net margin of 8.64%.The business had revenue of $493.77 million for the quarter, compared to analyst estimates of $486.23 million. During the same quarter last year, the company earned $0.51 EPS. Pediatrix Medical Group’s revenue was down 1.7% compared to the same quarter last year. On average, equities analysts forecast that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current year.

Insider Transactions at Pediatrix Medical Group

In related news, CEO Mark S. Ordan sold 23,000 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $22.41, for a total transaction of $515,430.00. Following the completion of the transaction, the chief executive officer directly owned 302,805 shares in the company, valued at $6,785,860.05. This represents a 7.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.90% of the stock is owned by corporate insiders.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.